OK, so it’s not quite as impactful as a meteorite shower in the Urals, but this week’s editorial does have a bit of a “go” at one particular segment of the medtech industry.
No, it’s not regulators. No, it’s not medtech companies. It’s not even sales reps, who we conclude remain an essential component in the symbiotic relationship between business and healthcare.
But after years of watching market “intelligence” companies peddle their wares we thought we might just ask the question. And having bought these things on more than one occasion, we’re urging caution. Five big ones for something you already knew can look like great value if you need to support your assertions, but it’s a lot of brass in anyone’s language.
Read this weeks rant, here.